FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | <b>OF CHANGE</b> | S IN BENEF | FICIAL OV | VNERSHIP |
|-----------|------------------|------------|-----------|----------|

| OMB APPRO             | JVAL      |
|-----------------------|-----------|
| OMB Number:           | 3235-0287 |
| Estimated average bur | den       |
| hours per response:   | 0.5       |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Troendle August J.                     |  |  |   | 2. Issuer Name and Ticker or Trading Symbol Medpace Holdings, Inc. [ MEDP ] |                                      |   |                   |   |  |  |                               |                  | 5. Relationship of Re<br>(Check all applicable)<br>X Director                                       |                              |  | <b>X</b>   | ( 10% O  | (s) to Issuer  10% Owner  Other (specify |   |  |  |
|--|--|--|---|---|--------------------------------------|---|-------------------|---|--|--|-------------------------------|------------------|---|------------------------------|--|--|--|--|---|--|--|
|  | ast) (First) (Middle) O MEDPACE HOLDINGS, INC. B75 MEDPACE WAY   |  |   |   |                                      | 3. Date of Earliest Transaction (Month/Day/Year) 08/31/2021 |                   |   |  |  |                               |                  |   |                              | X Officer (give title Other (s below)  CEO     |  |  |  |   |  |  |
| (Street) CINCIN  |  |  | .522<br>Zip)                            | 7   | 4. If <i>i</i>                       | Amend   | ment, [           | Date o                                  | ate of Original Filed (Month/Day/Year) |  |                               |                  |   |                              | 6. Indi<br>Line)<br>X                          | ·  |  |  |   |  |  |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |  |  |   |   |                                      |   |                   |   |  |  |                               |                  |   |                              |  |  |  |  |   |  |  |
| Date   |  |  | 2. Transaction<br>Date<br>(Month/Day/Ye | Executio  |                                      | n Date,   | Ti<br>C           | 3.<br>Transaction<br>Code (Instr.<br>8) |  | 4. Securities Acquired (A) o<br>Disposed Of (D) (Instr. 3, 4 a |                               |                  |   | and 5) Secur<br>Bene<br>Owne |  | ially<br>Following   | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) |  | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership |  |  |
|  |  |  |   |   |                                      |   | С                 | Code V                                  |  | Amoun  |                               | (A) or<br>(D)    | or Price  |                              | Reported<br>Transaction(s)<br>(Instr. 3 and 4) |  |  |  | (Instr. 4)  |  |  |
| Common Stock   |  |  |   | 08/31/202   | 1                                    |   | 5                 | S <sup>(1)</sup>                        |  | 12,67  | 5 <sup>(1)</sup>              | D                | \$182.04 <sup>(2)</sup>   |                              | 6,002,344                                      |  |  | I  | By<br>Medpace<br>Investors,<br>LLC <sup>(3)</sup>   |  |  |
| Common Stock   |  |  | 09/01/202                               | 21  |                                      |   | S                 |   |  | 14,30  | 14,304 <sup>(1)</sup> D \$186 |                  | \$186   | .29(4)                       | 29 <sup>(4)</sup> 5,988,040                    |  |  | I  | By<br>Medpace<br>Investors,<br>LLC <sup>(3)</sup>   |  |  |
| Common Stock   |  |  |   |   |                                      |   |                   |   |  |  |                               |                  | 706,643   |                              | 6,643  |  | D  |  |   |  |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |   |   |                                      |   |                   |   |  |  |                               |                  |   |                              |  |  |  |  |   |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                              | rivative Conversion Date Execution Date, Transaction of Code (Instr. Derivative or Exercise (Month/Day/Year) if any                          |  |   |   | ative<br>ities<br>red<br>sed<br>3, 4 | Expiration Date (Month/Day/Year) es d [ ]                   |                   |   |  | Amou<br>Secur<br>Unde<br>Deriv<br>Secur                        | Amount of De Securities Se    |                  | 8. Price of Derivative Security Instr. 5)  Beneficial Owned Following Reported Transacti (Instr. 4) |                              | ly   | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4)                                |  |   |  |  |
|  |  |  | Code                                    | v   | (A)                                  | (D)   | Date<br>Exercisal |   |  | ration   | Title                         | or<br>Numb<br>of |   |                              |  |  |  |  |   |  |  |

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$180.82 to \$185.00. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$181.575 to \$187.78. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 09/02/2021 **Troendle** 

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.